Replies to post #128564 on Biotech Values

[DewDiligence]

We were not able to show the superiority of this high-dose approach and we are still analyzing the data as far as the PRN versus monthly comparison.

If the monthly results were better than the results for PRN (the de facto standard in actual practice), Roche and NVS would presumably have finished “analyzing” the comparison data by now.